| http://www.w3.org/ns/prov#value | - In December 2006, we acquired intellectual property and other assets from Valeant Research & Development, Inc. (???Valeant???) related to RDEA806 and our next generation non-nucleoside reverse transcriptase inhibitor (???NNRTI???) program, as well as BAY 86-9766 (RDEA119) and our next generation MEK inhibitor program.
|
